Recently, the combination of atezolizumab (anti-PD-L1 monoclonal antibody) and bevacizumab resulted in superior OS than sorafenib in the first-line treatment of patients with advanced HCC (12), which suggested that improving the efficacy of immunotherapy may depend on combined treatment. Here, CD274 is linked to hepatocellular carcinoma.